132 related articles for article (PubMed ID: 35380016)
21. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study.
Jeong H; Shin J; Jeong JH; Kim KP; Hong SM; Kim YI; Ryu JS; Ryoo BY; Yoo C
ESMO Open; 2021 Jun; 6(3):100119. PubMed ID: 33901869
[TBL] [Abstract][Full Text] [Related]
23. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Al-Toubah T; Morse B; Pelle E; Strosberg J
Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478
[TBL] [Abstract][Full Text] [Related]
26. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Wang W; Zhang Y; Peng Y; Jin KZ; Li YL; Liang Y; Tan HY; Yu XJ; Zhou ZW; Chen J
Neuroendocrinology; 2021; 111(8):752-763. PubMed ID: 32668427
[TBL] [Abstract][Full Text] [Related]
27. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience.
Sahu A; Jefford M; Lai-Kwon J; Thai A; Hicks RJ; Michael M
J Oncol; 2019; 2019():9032753. PubMed ID: 30915122
[TBL] [Abstract][Full Text] [Related]
28. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Uncu D
J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
[TBL] [Abstract][Full Text] [Related]
29. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Rogowski W; Wachuła E; Gorzelak A; Lebiedzińska A; Sulżyc-Bielicka V; Iżycka-Świeszewska E; Żołnierek J; Kos-Kudła B
Endokrynol Pol; 2019; 70(4):313-317. PubMed ID: 30843182
[TBL] [Abstract][Full Text] [Related]
31. Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Nakano-Tateno T; Satou M; Inoshita N; van Landeghem FKH; Easaw J; Mehta V; Tateno T; Chik CL
Endocr Pathol; 2021 Sep; 32(3):418-426. PubMed ID: 32833164
[TBL] [Abstract][Full Text] [Related]
32. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL; Graham NT; Catalano PJ; Nimeiri HS; Fisher GA; Longacre TA; Suarez CJ; Martin BA; Yao JC; Kulke MH; Hendifar AE; Shanks JC; Shah MH; Zalupski MM; Schmulbach EL; Reidy-Lagunes DL; Strosberg JR; O'Dwyer PJ; Benson AB
J Clin Oncol; 2023 Mar; 41(7):1359-1369. PubMed ID: 36260828
[TBL] [Abstract][Full Text] [Related]
33. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Cives M; Ghayouri M; Morse B; Brelsford M; Black M; Rizzo A; Meeker A; Strosberg J
Endocr Relat Cancer; 2016 Sep; 23(9):759-67. PubMed ID: 27552969
[TBL] [Abstract][Full Text] [Related]
34. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
Liu AJ; Ueberroth BE; McGarrah PW; Buckner Petty SA; Kendi AT; Starr J; Hobday TJ; Halfdanarson TR; Sonbol MB
Oncologist; 2021 May; 26(5):383-388. PubMed ID: 33496040
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Spada F; Maisonneuve P; Fumagalli C; Marconcini R; Gelsomino F; Antonuzzo L; Campana D; Puliafito I; Rossi G; Faviana P; Messerini L; Barberis M; Fazio N
Endocrine; 2021 Apr; 72(1):268-278. PubMed ID: 32700133
[TBL] [Abstract][Full Text] [Related]
36. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Kesavan M; Grover P; Lam WS; Claringbold PG; Turner JH
Endocr Relat Cancer; 2021 Jun; 28(7):521-527. PubMed ID: 34010146
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
38. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract][Full Text] [Related]
39. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
40. Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Soulen MC; van Houten D; Teitelbaum UR; Damjanov N; Cengel KA; Metz DC
Pancreas; 2018 Sep; 47(8):980-984. PubMed ID: 30028446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]